Related Experiment Videos
Her-2/neu and breast cancer
1Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Summary
This review covers the Her-2/neu proto-oncogene in breast cancer. It discusses its role in prognosis, the targeted therapy Herceptin, and diagnostic testing methods.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Breast cancer is a leading malignancy in women.
- The Her-2/neu (c-erb-B2) proto-oncogene is a key factor in breast cancer prognosis and treatment.
- Her-2/neu overexpression correlates with poorer patient outcomes.
Purpose of the Study:
- To provide a comprehensive review of Her-2/neu in breast cancer.
- To discuss the biological significance, prognostic and predictive value of Her-2/neu.
- To cover targeted therapy with Herceptin and laboratory testing methods.
Main Methods:
- Literature review of Her-2/neu in breast cancer.
- Analysis of biological function and clinical significance.
- Review of Herceptin therapy and diagnostic assays.
Main Results:
- Her-2/neu status is critical for breast cancer management.
- Overexpression/amplification of Her-2/neu indicates a worse prognosis.
- Herceptin targets Her-2/neu-positive breast cancer.
Conclusions:
- Her-2/neu is a vital biomarker in breast cancer.
- Understanding Her-2/neu is essential for effective treatment strategies.
- Targeted therapy and accurate testing are crucial for Her-2/neu-positive breast cancer.